

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

February 23, 2021  
Date of Report (date of earliest event reported)

TransEnterix, Inc.  
(Exact name of Registrant as specified in its charter)

Delaware  
(State or other jurisdiction of  
incorporation or organization)

0-19437  
(Commission  
File Number)

11-2962080  
(I.R.S. Employer  
Identification Number)

635 Davis Drive, Suite 300  
Morrisville, North Carolina 27560  
(Address of principal executive offices)

919-765-8400  
(Registrant's telephone number, including area code)

Not Applicable  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol	Name of each exchange on which registered
Common Stock \$0.001 par value per share	TRXC	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

## Item 7.01 Regulation FD Disclosure

On February 23, 2021, TransEnterix, Inc., a Delaware corporation (the “Company”) is holding an Investor Day conference. Among the topics to be discussed, the Company announced its corporate name change to Asensus Surgical, Inc. The Investor Day presentation is furnished herewith as Exhibit 99.1.

The information included herein and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

## Item 8.01 Other Events

On February 23, 2021, the Company also issued a press release announcing its name change, effective February 23, 2021, and a change of its trading symbol to ASXC, to be effective on March 5, 2021. The press release is filed herewith as Exhibit 99.2.

## Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

99.1	<a href="#">Investor Day Presentation, dated February 23, 2021</a>
99.2	<a href="#">Press Release, dated February 23, 2021</a>
104	Cover Page Interactive Data File (formatted in inline XBRL)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: February 23, 2021

**TRANSENERIX, INC.**

By: /s/ Shameze Rampertab

Shameze Rampertab

Executive Vice President and Chief Financial Officer



## INVESTOR DAY PRESENTATION

February 23, 2021

Anthony Fernando, President & CEO


Shameze Rampertab, EVP & CFO

© 2021 Asensus Surgical, Inc.

## Forward Looking Statements

This presentation includes statements relating to our vision for the future of performance-guided surgery and the role the Senhance® Surgical System may play. These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations, and include whether we will be well-positioned to continue to deliver on our strategy and bring transformative technology to surgeons, hospitals and patients globally. For a discussion of the risks and uncertainties associated with our business, please review our filings with the Securities and Exchange Commission (SEC).

You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this presentation and speak only as of the date this presentation was first made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.





Global  
Regulatory  
Approvals



Global  
Training Centers



**100+**  
Active Surgeon  
Users



Active  
Clinical Sites in  
US, EU & Asia



**4,000+**  
Surgeries  
Performed



Robust  
Intellectual Property  
Portfolio



**1st**  
eye-sensing camera control  
haptic feedback  
3 mm robotic instruments  
augmented intelligence and machine vision  
real-time surgical image analytics  
pediatrics with robotic 3 mm



Strong  
Talented Global  
Team



Integrated  
Remote  
Mentoring



We believe in digitizing the interface between the surgeon and patient to pioneer a new era of **Performance-Guided Surgery** by **unlocking the Clinical Intelligence** to **enable consistently superior outcomes** and a **new standard of surgery.**



# The Reality of Surgery

1 in 5 patients undergoing surgery has  
1 or more complications\*



**Overall profit margin decreased from 5.8% for patients without complications to 0.1% for patients with complications.\*\***

Essentially, hospitals make **no money if there is a complication.**



**Unintended and preventable surgical complications are rampant** and cost health systems billions of dollars each year




**Limited technological innovation** (robotics is 20 years old)




**Lack of access to critical real-time information**

# Surgical Decision Chain



# Something is Missing



Minimal innovation to improve decision-making aspects in the high-pressure, highly-variable situations that repeatedly occur during surgery.



# We Should Expect More From Surgery

ASENSUS  
SURGICAL

## Holistic approach to addressing each phase of the surgical decision chain

- **Increase safety** for better outcomes which lead to better patient and provider satisfaction
- **Reduce surgical variability** and factors that contribute to poor outcomes
- **Guide surgeons** to successfully navigate when unexpected events occur to effectively reduce surgical errors and complications
- **Provide real-time clinical intelligence** and capabilities to create more predictable outcomes to meet value-based care constraints


© 2021 Asensus Surgical, Inc.




## Prof. Dr. Jaap Bonjer

Professor of Surgery, Amsterdam University Medical Centre  
CEO, Amsterdam Skills Centre


(VIDEO PRESENTATION)



# Evolution of Surgery



# Performance-Guided Surgery




Improved Decision Making

Improved Collaboration

Improved Predictability

# Reimagine Surgery

## Technology and the Surgical Value Chain



Surgeon capabilities scale as you add technical capabilities, resulting in **increased predictability** and **superior outcomes**

# Surgical Paradigm

## Mapping Categories to the Surgical Value Chain

### Laparoscopy

Manual Control

### Robotic Surgery

Robotic Precision and Control

### Digital Laparoscopy


Advanced Sensing, Digital Insights

### Performance-Guided Surgery

Intelligent Preparation, Perceptive Real-Time Guidance




# Technology Video Presentation



# Unlocking Clinical Intelligence

## The Surgical Assurance Framework





## Dr. Amit Trivedi

Chairman, Department of Surgery  
Hackensack Meridian Health at Pascack Valley

(VIDEO PRESENTATION)



# Market Drivers

## Why the Time is Now



Value-based healthcare is rapidly shifting the responsibility for quality outcomes and inefficiency to hospitals and physicians.\*



COVID-19 has exposed the shocking financial frailty of hospital systems as well as capacity and resource constraints, which must be bolstered and requires an acceleration of our innovation.\*\*




Patients' conditions are becoming more complex and therefore treating them becomes more complicated. The absolute number of patients seeking care is increasing, and many more patients have multiple chronic conditions than they did a generation, or even a decade, ago.\*\*\*



The technology exists and is building in other industries with computational technology growing exponentially. Why not bring it to surgery where it is prime for adoption?


# Global Market Trends in Surgical Robotics



SURGICAL ROBOTICS IS A LARGE AND FAST-GROWING MARKET AND CONVERTING LAPAROSCOPIC SURGERY IS A GREENFIELD OPPORTUNITY



Worldwide Robotic Penetration Rate is < 5%, Today



Current Robotics Market

Open Surgery  
37mm procedures

↓  
Current Robotic Penetration < 5%

Digital Laparoscopy

Laparoscopic Surgery  
16mm procedures

↓  
Greenfield Opportunity for Senhance

Sources: Goldman Sachs Global Investment Research, Healthcare Cost and Utilization Project (HCUP), Global Market Insights, Mordor Intelligence, company analysis

© 2021 Asensus Surgical, Inc.

# Our Path to Market Leadership

## Senhance



Robust Digital Laparoscopy platform built on the fundamentals of MIS

## Intelligent Surgical Unit™ (ISU™)



Digital Platform capable of machine vision and augmented intelligence to enable real-time surgical analytics

## Performance-Guided Surgery



Clinical Intelligence to unlock superior outcomes with surgery

**Global organizational footprint and installed base**


**Continued focus and targeted investments that drive innovation to create the future of surgery**



© 2021 Asensus Surgical, Inc.


# Surgery Reimagined

Performance-Guided Surgery – next  
level technology that completely  
changes the idea of what's possible.



# A SENSUS

S U R G I C A L



**FOR IMMEDIATE RELEASE****TransEnterix Announces Name Change to Asensus Surgical and Introduces a New Category of Surgery, Performance-Guided Surgery**

*New name reflects commitment to pioneering a new era of Performance-Guided Surgery to help improve surgical results and patient outcomes*

**RESEARCH TRIANGLE PARK, N.C.**--(BUSINESS WIRE)--February 23, 2021-- TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that it will change its corporate name to Asensus Surgical, Inc. The name change reflects the company's broader vision of shaping the future of surgery by integrating computer vision and machine learning with surgical robotics. While the company name change is effective today, the company's stock will begin trading under the new ticker symbol, NYSE American: ASXC, and name, Asensus Surgical, Inc., at the open of trading on March 5, 2021.

Asensus Surgical's technology platform, Senhance® Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning. Senhance goes beyond the typical surgical robotic systems, providing surgical assurance through haptic feedback, eye-tracking camera control, and 3D visualization, and is the first platform to offer 3 mm instruments (the smallest instrument available in the world on a robotic surgical platform). Today, the Senhance Surgical System is being used by over 100 active surgeon users across three continents with over 4,000 procedures performed across a wide variety of surgical specialties.

"As we work to create the future of surgery we need to enable surgeons to take the best surgical practices and techniques from everywhere and enable them to be leveraged anywhere; this is what digital technology has enabled us to do," said Anthony Fernando, President and Chief Executive Officer of Asensus. "As the company evolves from a robotics company to a digital surgery company, the rebrand better reflects our vision and we know that Asensus has the technology, the team, and the opportunity to create a new paradigm in best surgical practices and techniques we call performance-guided surgery."

Sensus is Latin for "cognition," making the connection between surgeons' knowledge and the augmented intelligence technology to perceive and develop future innovations. The inclusion of the "A" in front of "sensus" lends itself to the idea of augmented intelligence and being at the forefront of innovation. Asensus also speaks to "ascending" and "elevating," which speaks to the company's mission to elevate robotic surgery: to drive predictable outcomes, to optimize resources and costs, and to work with hospital systems that seek to strive to employ innovative healthcare strategies.

---

As part of the name change, Asensus Surgical also released a new company logo and rebranded the company website at [www.Asensus.com](http://www.Asensus.com).

### **About Asensus Surgical, Inc.**

Asensus Surgical, Inc. is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery by unlocking the Clinical Intelligence to enable consistently superior outcomes and a new standard of surgery. This builds upon the foundation of Digital Laparoscopy with the Senhance® Surgical System powered by the Intelligent Surgical Unit™ (ISU™) to increase surgeon control and reduce surgical variability. With the addition of machine vision, augmented intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. Learn more about Performance-Guided Surgery and Digital Laparoscopy with the Senhance Surgical System here: [www.Senhance.com](http://www.Senhance.com). Now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: [www.transenterix.com/indications-for-use/](http://www.transenterix.com/indications-for-use/).

### **Forward-Looking Statements**

This press release includes statements relating to our vision for the future of performance-guided surgery and the role the Senhance Surgical System may play. These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations, and include whether we will be well-positioned to continue to deliver on our strategy and bring transformative technology to surgeons, hospitals and patients globally. For a discussion of the risks and uncertainties associated with our business, please review our filings with the Securities and Exchange Commission (SEC). You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

### **INVESTOR CONTACT:**

Mark Klausner or Mike Vallie, +1 443-213-0499

[invest@transenterix.com](mailto:invest@transenterix.com)

**Or**

### **MEDIA CONTACT**

Kristin Schaeffer

CG Life

858-354-8850

[kschaeffer@cglife.com](mailto:kschaeffer@cglife.com)